Why the Vanguard Healthcare Fund (VGHCX) Is Dropping

Why the Vanguard Healthcare Fund Drop Deserves a Closer Look

The Vanguard Healthcare Fund (VGHCX) has underperformed expectations in recent years, and the reasons go well beyond generic "macro headwinds." For investors holding $500K or more in this fund inside taxable accounts, the current drawdown is simultaneously a tax planning opportunity and a signal to reassess whether a sector fund built around pharmaceutical giants still does what you think it does.

VGHCX launched in 1984 and has navigated multiple market cycles. But the structural forces pressing on it today are different from anything in its prior history: a multi-year federal drug pricing regime, a GLP-1 drug revolution that is reshaping winners and losers within the same portfolio, and an expense ratio that costs 22 basis points more than its passive sibling VHT. None of that is obvious from a standard fund screener.

Why Is the Vanguard Healthcare Fund Dropping in 2024?

The short answer: regulatory repricing, not broad economic weakness.

The Inflation Reduction Act's Medicare drug price negotiation provisions began with 10 drugs in 2023 and expand to 15 additional drugs in 2027. According to the Congressional Budget Office, these provisions are projected to meaningfully reduce federal prescription drug spending, which directly compresses revenue forecasts for the large-cap pharmaceutical companies that anchor VGHCX's top holdings.

This is not an episodic political risk that clears after an election cycle. It is a structural repricing of pharmaceutical earnings power, baked into law, with an expanding scope over the next several years. Investors treating the current drawdown as a simple buying opportunity may be underestimating how durable this headwind is.

Healthcare sector funds have historically carried a beta below 1.0 relative to the S&P 500, which supports the "defensive" framing most investors apply to them. But that framing breaks down when the risk is policy-driven rather than cyclical. In 2016 (drug pricing political risk), 2019 (Medicare for All debate), and 2022 through 2023 (IRA passage), healthcare underperformed the broader market during periods of general equity strength. The sector's risk profile has become more policy-correlated than it was a decade ago, which matters enormously for anyone using it as a portfolio stabilizer.

The GLP-1 story adds another layer. Eli Lilly and Novo Nordisk have seen dramatic valuation increases on the back of semaglutide and tirzepatide. Meanwhile, medical device companies focused on bariatric surgery and cardiovascular interventions have faced direct headwinds from the same drugs. VGHCX holds both sides of that trade. What looks like "healthcare diversification" is, in practice, a concentrated bet on how the GLP-1 revolution resolves.

What Are the Top Holdings in VGHCX and How Does GLP-1 Exposure Shape Performance?

According to Vanguard's official fund disclosures, VGHCX's top holdings are concentrated in large-cap names including UnitedHealth Group, Johnson & Johnson, and Eli Lilly. These three companies alone represent a substantial share of the fund's net assets, which means individual stock events move the fund materially.

The GLP-1 bifurcation is the dominant performance driver in 2023 and 2024. Eli Lilly's weight-loss and diabetes drug pipeline has made it one of the strongest performers in the S&P 500. But that same drug category is pressuring cardiac device makers, surgical robotics companies, and bariatric-focused businesses that also sit inside VGHCX.

The FDA's novel drug approval rate also matters here. According to FDA data, approval rates for novel drugs directly influence biotech and pharmaceutical valuations. A slowdown in approvals creates measurable volatility in funds with significant biotech exposure, and VGHCX carries meaningful biotech weight alongside its large-cap core.

For investors in investing in pharmaceuticals and biotech, understanding this internal bifurcation is more useful than watching the fund's headline NAV.

How Has VGHCX Performed Over the Last 10 Years Versus Its Benchmarks?

Morningstar tracks VGHCX's historical returns, expense ratio, category ranking, and risk-adjusted performance metrics against the MSCI US IMI Health Care 25/50 benchmark. The fund's active management has delivered periods of meaningful outperformance during sector rotations, particularly when its managers correctly positioned around drug approval cycles or managed care earnings surprises.

The relevant comparison set for a sophisticated investor is not just VGHCX versus its own history. It is VGHCX versus VHT (passive, 0.10% expense ratio) and XLV (S&P 500 healthcare, the most liquid large-cap proxy) on an after-tax, after-fee basis.

The 22 basis point expense ratio gap between VGHCX and VHT compounds significantly on a large position. On a $1M allocation, that is $2,200 per year in additional costs before any performance differential. Over 10 years, assuming similar gross returns, the passive option retains roughly $25,000 more in capital (before compounding). Whether VGHCX's active management generates enough alpha to justify that gap is a legitimate question, and the honest answer is: sometimes yes, sometimes no, and the periods of outperformance are not reliably predictable.

For a deeper look at how these two structures compare for large taxable accounts, see ETFs versus mutual funds for healthcare exposure.

What Is the Difference Between VGHCX and VHT for Large Taxable Accounts?

This is where the analysis gets genuinely useful for FatFIRE-level portfolios.

VGHCX is a mutual fund. It distributes capital gains annually, which creates taxable events you cannot control. In years when the fund's managers sell appreciated positions, you receive a capital gains distribution even if you did not sell a single share. For investors in the 37% federal bracket with the 3.8% net investment income tax layered on top, that distribution can cost 23.8 cents on every dollar of long-term gain distributed.

VHT is an ETF tracking the same underlying index as VGHCX's benchmark. The ETF structure allows in-kind redemptions that largely eliminate capital gains distributions. You control when you realize gains. That structural advantage is worth real money on a $500K+ position over a multi-decade holding period.

The counterargument for VGHCX: active management has historically added value during specific healthcare market dislocations. If you believe the current drawdown is one of those moments, the active manager's ability to rotate within the sector may justify the higher cost and lower tax efficiency.

Vanguard's capital market assumptions provide useful context for modeling expected returns across both structures over a 10-year horizon.

Should You Tax-Loss Harvest Your Healthcare Fund Position During a Sector Drawdown?

For investors in the top federal bracket, a 10 to 15% drawdown in VGHCX is not just a paper loss. It is a potential tax asset.

The math is concrete. On a $1M VGHCX position with a 12% drawdown, you are sitting on $120,000 in realizable losses. At the 37% federal rate plus 3.8% NIIT, offsetting $120,000 of short-term gains saves approximately $49,560 in federal taxes. Against long-term gains at 20% plus NIIT, the savings are approximately $28,800. Either way, this is not a rounding error.

The IRS wash-sale rule, as detailed in IRS Publication 550, prohibits claiming a loss if you purchase a "substantially identical" security within 30 days before or after the sale. The critical question is whether VHT and VGHCX are substantially identical. They track the same benchmark, which creates real wash-sale risk. Switching to XLV (which tracks the S&P 500 healthcare subset rather than the broader MSCI US IMI Health Care 25/50 index) may provide sufficient differentiation to avoid wash-sale treatment while maintaining sector exposure. This determination requires qualified tax counsel. Do not make it unilaterally.

Research published in the Journal of Financial Planning demonstrates that systematic tax-loss harvesting in taxable accounts generates meaningful after-tax alpha, particularly for high-income investors holding concentrated sector fund positions. The alpha is not from market timing. It is from converting unrealized losses into usable tax offsets before they recover.

The replacement security decision matters as much as the harvest decision. If you sell VGHCX and park in cash or a money market for 31 days, you have eliminated sector exposure during what may be a recovery period. A more sophisticated approach is to move into XLV immediately, maintain healthcare exposure, and revisit the VGHCX position after the wash-sale window closes.

How Does VGHCX Compare to Fidelity Select Health Care Portfolio (FSPHX)?

Both VGHCX and FSPHX are actively managed healthcare sector funds with long track records. The differences are meaningful for large-account holders.

FSPHX carries a 0.44% expense ratio versus VGHCX's 0.32%, making Vanguard's fund cheaper on a gross basis. FSPHX has historically maintained a heavier tilt toward biotech and specialty pharmaceuticals, which creates higher volatility but also higher upside in drug approval cycles. VGHCX tends to be more balanced across managed care, large-cap pharma, devices, and biotech.

During the 2022 to 2023 IRA-driven selloff in large-cap pharma, the funds' different weighting approaches produced divergent outcomes. Neither fund is obviously superior across all market environments. The relevant question for a FatFIRE investor is not which fund "won" over a trailing period, but which fund's sector tilts align with your own view on where healthcare earnings growth will come from over the next five to seven years.

For context on how Vanguard's overall fund lineup and management philosophy compare to competing asset managers, see how Vanguard compares to BlackRock.

What Percentage of a $5M+ Portfolio Should Go to Healthcare Sector Funds?

Standard 60/40 guidance has nothing useful to say to someone with a $5M+ portfolio, a tax attorney, and real concentration decisions to make. So let's be direct.

Healthcare sector funds serve two potential roles in a large portfolio: defensive ballast (lower beta, non-cyclical demand) and growth exposure (biotech, GLP-1 innovation, aging demographics). The problem is that VGHCX is no longer cleanly either. Its policy correlation has increased, its internal GLP-1 bifurcation creates idiosyncratic risk, and its large-cap pharma core faces a multi-year regulatory headwind.

A reasonable framework for a $5M+ taxable portfolio:

A 5 to 8% allocation to healthcare sector exposure is defensible as a satellite position within a broader equity allocation. Above 10%, you are making an active sector bet that requires a specific thesis, not just a "healthcare is defensive" assumption. If you are already holding individual positions in Eli Lilly, UnitedHealth, or other large healthcare names through direct indexing or a concentrated stock strategy, your effective healthcare exposure is likely higher than your fund allocation suggests.

For investors considering healthcare private equity trends as an alternative to public market sector funds, the illiquidity premium and access to earlier-stage innovation may be more compelling than a mutual fund that largely mirrors what you can get cheaper through VHT.

The Federal Reserve Bank of St. Louis employment data confirms that healthcare remains one of the largest and most consistently growing employment sectors in the U.S. economy, which supports the long-term structural demand thesis. But structural demand does not automatically translate into equity returns when earnings are being repriced by legislation.

Is VHT a Better Long-Term Investment Than VGHCX for High-Net-Worth Portfolios?

For most FatFIRE investors holding healthcare exposure in taxable accounts, VHT is the structurally superior vehicle. Lower expense ratio, better tax efficiency, same benchmark exposure. The case for VGHCX rests entirely on whether its active management generates enough after-tax, after-fee alpha to overcome those disadvantages.

The honest assessment: over long periods, the evidence for active management outperformance in large-cap U.S. healthcare is mixed. Morningstar's fund analysis shows VGHCX has delivered periods of meaningful outperformance versus its benchmark, but consistency is the challenge. You are paying 22 basis points annually for alpha that may or may not materialize.

For investors who want active management exposure to healthcare without the tax drag of a mutual fund, the best Vanguard funds for income-focused investors analysis provides a useful framework for thinking about fund selection within tax-advantaged versus taxable account structures.

One underappreciated consideration: if you hold VGHCX inside a tax-advantaged account (IRA, 401(k)), the tax efficiency argument for VHT disappears. Inside a tax-deferred wrapper, the active management potential of VGHCX and the passive efficiency of VHT are on equal footing, and the decision reduces to a pure cost-versus-alpha question.

Portfolio Positioning: Practical Decisions for the Current Drawdown

The vanguard healthcare fund drop creates three distinct decision points, depending on your situation.

If you hold VGHCX in a taxable account with unrealized losses: Model the tax-loss harvest against your current capital gains position. The XLV replacement strategy is worth discussing with your tax attorney before year-end. Do not let the wash-sale clock expire without a plan.

If you hold VGHCX in a taxable account with large embedded gains: The cost of switching to VHT may exceed the expense ratio savings for several years. This requires after-tax modeling, not a simple fee comparison. A $500K position with $200K in embedded gains carries a switching cost of roughly $47,600 in federal taxes (at 23.8%) before you save a single dollar in fees.

If you hold VGHCX in a tax-advantaged account: Evaluate whether the active management premium is justified. If not, VHT or XLV inside the same account captures the sector exposure at lower cost with no tax consequence for the switch.

For investors exploring low volatility strategies during market turbulence as a complement to sector fund exposure, the current environment makes a reasonable case for pairing healthcare with lower-correlation assets rather than doubling down on sector concentration.

Recent leadership changes at Vanguard are worth monitoring for any signals about strategic shifts in how the firm manages its active fund lineup, including VGHCX.

For investors weighing whether to complement or replace sector fund exposure with broader diversification tools, alternative strategies for portfolio diversification covers several approaches relevant to $5M+ portfolios.

References

• Morningstar -- Vanguard Health Care Fund (VGHCX) Fund Analysis and Performance Data (2024)
• Vanguard -- Vanguard Health Care Fund Investor Shares (VGHCX) Prospectus and Fact Sheet (2024)
• S&P Global / SPDR -- Health Care Select Sector SPDR Fund (XLV) Performance and Holdings (2024)
• Congressional Budget Office -- Medicare Drug Price Negotiation: Budgetary Effects of the Inflation Reduction Act (2022)
• U.S. Food and Drug Administration -- Novel Drug Approvals for 2023 (2023)
• IRS -- Publication 550: Investment Income and Expenses, Wash-Sale Rules (2023)
• Journal of Financial Planning -- Tax-Loss Harvesting in Taxable Portfolios: Quantifying the Tax Alpha (2020)
• Federal Reserve Bank of St. Louis (FRED) -- U.S. Health Care and Social Assistance Employment Data (2024)